Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Pabinger

Showing results (1-10 of 211) with videos related to

Pageof 22
Sort By:
Blut|August 1, 1986
Clinical relevance of protein CI Pabinger
Hamostaseologie|November 5, 2004
[Thrombophilia]I Pabinger
Wiener Medizinische Wochenschrift (1946)|June 23, 1999
[Monitoring blood coagulation]I Pabinger-Fasching
Wiener Medizinische Wochenschrift (1946)|January 1, 1991
[Blood coagulation disorders in leukemia]I Pabinger-Fasching
Acta Medica Austriaca|September 9, 1999
[Thromboembolism--genetic and acquired risk factors]I Pabinger-Fasching
Hamostaseologie|August 9, 2011
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic optionsC Ay, I Pabinger
Arteriosclerosis, Thrombosis, and Vascular Biology|June 1, 1996
Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural InhibitorsI Pabinger, B Schneider
Journal of Thrombosis and Haemostasis : JTH|August 17, 2005
Thrombophilia and pregnancy outcomesI Pabinger, R Vormittag
Hamostaseologie|August 9, 2011
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?I Pabinger, C Ay
Hamostaseologie|March 6, 2015
VTE risk assessment in cancer. Who needs prophylaxis and who does not?C Ay, I Pabinger
Pageof 22

Showing results (1-10 of 211) with videos related to

Sort By:
Pageof 22
Blut|August 1, 1986
Clinical relevance of protein CI Pabinger
Hamostaseologie|November 5, 2004
[Thrombophilia]I Pabinger
Wiener Medizinische Wochenschrift (1946)|June 23, 1999
[Monitoring blood coagulation]I Pabinger-Fasching
Wiener Medizinische Wochenschrift (1946)|January 1, 1991
[Blood coagulation disorders in leukemia]I Pabinger-Fasching
Acta Medica Austriaca|September 9, 1999
[Thromboembolism--genetic and acquired risk factors]I Pabinger-Fasching
Hamostaseologie|August 9, 2011
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic optionsC Ay, I Pabinger
Arteriosclerosis, Thrombosis, and Vascular Biology|June 1, 1996
Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural InhibitorsI Pabinger, B Schneider
Journal of Thrombosis and Haemostasis : JTH|August 17, 2005
Thrombophilia and pregnancy outcomesI Pabinger, R Vormittag
Hamostaseologie|August 9, 2011
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?I Pabinger, C Ay
Hamostaseologie|March 6, 2015
VTE risk assessment in cancer. Who needs prophylaxis and who does not?C Ay, I Pabinger
Pageof 22